Dataset opportunity
Isa Pharma — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Isa Pharma, usable for Diagnostic AI and Computer Vision.
Score
67.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Imaging Market to reach US$ 16.88 Billion by 2034 from US$ 1.70 Billion in 2024, growing at a CAGR of 25.8%.
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📝Published article
Scientific publications detailing clinical and immunological outcomes
source ↗
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Isa Pharma holds a highly specialized Medical Imaging Dataset derived from its clinical trials, featuring image modalities such as CT and MRI. This dataset is uniquely enriched with corresponding immunological and genomic data, medical records, and regulatory documentation, making it exceptionally well-suited for developing and validating sophisticated Diagnostic AI models, particularly in oncology and immunology.
The global market for AI in medical imaging is expanding rapidly, projected to grow from USD 1.70 billion in 2024 to USD 16.88 Billion by 2034, at a CAGR of 25.8%. While access is subject to GDPR and potential shared ownership agreements, the rarity and depth of this multi-modal data offer a significant competitive advantage for entities aiming to lead in the precision medicine and diagnostic AI space, justifying the negotiation of access. ⚠ Diligence (valuable data, access to negotiate): Clinical trial data is subject to strict medical privacy regulations (GDPR).; Data ownership may be shared in specific co-development programs (e.g., with Regeneron).; Highly specialized immunological and genomic datasets requiring expert interpretation. · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves Isa Pharma possesses a rare, proprietary dataset from its immunotherapy clinical trials, linking patient biomarkers and immune system reactions to concrete treatment outcomes. This is a critical asset for medical AI firms developing next-generation diagnostic AI to predict patient response to specific cancer therapies. In a market projected to grow at over 25% annually, this unique data on HPV16-positive cancers offers a significant competitive advantage for training and validating predictive algorithms in oncology.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand is extremely high, driven by the fierce competition in the AI in Medical Imaging market which is projected to grow at a CAGR of 25.8%, creating urgent demand for unique, high-quality training data.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 data-appetite signals (1 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — ISA Pharmaceuticals is a clinical-stage immunotherapy SME developing therapies for cancer and viral infections; the clinical trial data it generates, including medical imaging, is a valuable by-product of its core business, making it an ideal target. Issues: Pitchbook lists the company as 'Out of Business', which contradicts all other sources and recent news, but this should be clarified.
- Deep Qualification90
⚠ needs review — The target is a clinical-stage immunotherapy company whose R&D generates a highly valuable dataset (imaging, genomic, immunologic), but data access is severely restricted by regulatory frameworks (GDPR) and a complex partnership history with Regeneron, which recently ended for the lead asset. [licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
The company holds structured data from Phase I and II clinical trials, detailing patient response, safety, and efficacy metrics essential for training AI to predict treatment outcomes in oncology.
Industrial data
This represents proprietary data detailing T-cell responses and immune system activation, providing a unique longitudinal view crucial for AI models that aim to understand the mechanisms of immunotherapy efficacy.
Regulatory records
The dataset includes deep molecular and biomarker characterizations of trial participants, providing the granular, patient-level data necessary to develop and validate AI algorithms that can identify likely responders to therapy.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Isa Pharma Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging Market to reach US$ 16.88 Billion by 2034 from US$ 1.70 Billion in 2024, growing at a CAGR of 25.8% (source: Market.us). Investment score 67.8/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Microsure — Sensor Telemetry Dataset Opportunity
View opportunity →healthcareDocobo — Medical Imaging Dataset Opportunity
View opportunity →healthcareFilab — Industrial Operations Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- Data marketplaces, explained4 min read
- Data licensing, term by term4 min read
- Is Your Data Worth Money?3 min read